Jurgen Borlak was a Cancer Research Campaign-founded postdoctoral research scientist and in 1990 joined the Marion Merrel Dow Research Institute in Strasbourg, France, as principal investigator. In 1998, he was appointed Director of the Center of Drug Research and Molecular Pharmacology at the Fraunhofer Institute of Toxicology and Experimental Medicine; the centre focuses largely on the molecular effects of drugs and xenobiotics, using a wide range of methods and technologies in cell biology, genomics and molecular biology.

In 2000 Jurgen Borlak was habilitated in pharmacology and toxicology and received the venia legendi at the Medical School of Hannover. In 2002 he was appointed as full professor to the chair of Pharmaco- and Toxicogenomics at the Medical School of Hannover. He was also appointed as Professor of Molecular Anatomy at the Medical Faculty of the University Leipzig in 2003. Jurgen Borlak is author of 157 original publications and 25 book chapters. He is reviewer and member of the editorial board for various scientific journals. Amongst others he is member of the of the Council on Basic Cardiovascular Sciences and an appointed expert of the World Health Organisation.

Cédric has hold several positions in the pharmaceutical industry at Sanofi and Merck Serono. He participated to, then was responsible for developing the company's research knowledge space (corporate database and ELNs). He had tremendous impacts in implementing innovative solutions for integrating internal and external information as well as developing predictive tools related to drug-likeness, ADME, virtual screening, and in silico toxicology. Cédric has 10 years experience in the development of databases and computational methods in the pharma-industry.

Dr. Karol Kozak is currently working as data handling expert at LMC-RISC, ETH Zurich. He has been influential in the development of data mining tolls for High Throughput, High Content Screening (HCS) over the last few years at Max Planck Institute of Molecular Cell Biological and Genetic in Dresden (Germany).

He plays a leading Role in defining the strategy and standards for management of large scale data produced in HCS technology. During his PhD time Karol Kozak became an expert in statistical pattern recognition applied to large scale screening data. He performed various data managment and data mining projects at Max Planck Institute of Cell Biology and at ETH Zurich.

 

Harsukh completed his medical training at Aberdeen University  and post-graduate  clinical, academic  and research training in general internal medicine, immunology, respiratory medicine and oncology  at various teaching  hospitals in London including  St Bartholomew, Westminster  & Charing Cross Hospitals, London (Imperial Medical School, one of the top 3 biomedical institutions in the world).  

He joined Pfizer Central Research in 1994 in the Dept of Experimental Medicine as Clinical Project Manager/Associate Director  and worked on various anti-bacterial, anti-fungal, cardiovascular and oncology projects. Later he joined Roche Global Drug Development as Global Clinical Science Leader,  Director of Oncology and worked on various projects in oncology, virology, asthma and allergy.  Since 1998 he has been Director, Global Experimental Medicine, R & D Charnwood and in 2003 took on the additional role of Director, Global Discovery Medicine, Respiratory  & Inflammation Therapeutic Area and has had responsibility within his department for various projects in  Cardiovascular, Respiratory (Asthma, Rhinitis, COPD) and Inflammation (Rheumatoid arthritis, Osteoarthritis, Transplantation and Psoriasis).  

He chairs and leads the cross-functional Discovery Medicine Leadership Team (DMLT), comprising of department heads for Bioscience, Translational Science, Bioanalysis, Molecular Science & Biomics, Imaging, Safety Assessment, Clinical Pharmacology, Experimental Medicine and Clinical Sciences spread across 3 R & D sites, that spans both discovery and development functions.   Recently he has been appointed the Global Head of Early Development, Respiratory  & Inflammation Therapeutic Area

He has also served on the AZ, Human Exposure Limits Committee (HELC), which oversees all compounds that enter FTIM. He has published extensively (> 100 publications) and has been an invited keynote speaker at more than 100 international conferences and is cited in the Marquis Who Who for “demonstrating outstanding achievement” and “contributing significantly to the betterment of contemporary society”.

Shankar Sellappan, Ph.D. is an Industry Analyst with the Frost & Sullivan North American Healthcare Practise. He focuses on monitoring and analyzing emerging trends, technologies and market dynamics in Drug Discovery Technologies industry in North America.

Since joining Frost & Sullivan in February 2006, Dr. Selappan has completed several studies, including analysis of the U.S. Life Science Mass Spectrometry, U.S qRT-PCr markets, and U.S. Protein Electrophoresis market. As as a former scientist, his market analyses are written from an end-user perspective, with applications playing a prominent role in the development of market revenue forecast.

Prior to joining Frost & sulivan, Dr. Selleppan was a graduate student at University of Texas M.D. Anderson Cencer Center. He brings significant practical expirience in the use of life science reseach technologies, which he acquired in a variety of medical research disciplines at the UTMDACC and Schools of Medicine of Johns Hopkins University and Case Western Reserve University.

Dr Jeffrey Norenberg, MS, Pharm D, is Associate Professor of Pharmacy and Director of Radiopharmaceutical Sciences at the University of New Mexico and the Director of the Keck-UNM Small Animal Imaging Resource.
Dr. Norenberg has expertise in the clinical pharmacology and targeted therapies in oncology. His work focuses on targeted delivery of radiopharmaceuticals for diagnosis and therapy and the translation from basic to pre-clinical and clinical research. Dr. Norenberg was a co-investigator in the first US clinical trials of somatostatin targeting radiopharmaceuticals for therapy of neuroendocrine tumors. Dr Norenberg maintains a small-scale cGMP laboratory to provide novel parenterals for clinical studies.